Conventional osteosarcoma of the mandible successfully treated with radical surgery and adjuvant chemotherapy after responding poorly to neoadjuvant chemotherapy: a case report

Abstract

BackgroundOsteosarcoma, the most common primary bone malignancy, has an extremely poor prognosis and a high rate of local recurrence and distal metastases. Because osteosarcomas of the head and neck region are rare, accounting for less than 10% of all osteosarcoma cases, limited information is available about their treatment and prognosis. Because of the high rate of distal metastases associated with extragnathic osteosarcoma, surgery combined with chemotherapy is currently considered essential in its treatment. However, the role of chemotherapy has not been well elucidated in the treatment of head and neck osteosarcoma because of the rarity of this condition.Case presentationIn this report, we present the case of a 58-year-old Japanese woman with osteosarcoma of the mandible that was treated with radical surgery combined with neoadjuvant and adjuvant chemotherapy. Because the tumor showed rapid growth during neoadjuvant chemotherapy, neoadjuvant chemotherapy was suspended and surgical resection was performed, followed by adjuvant chemotherapy. No evidence of local recurrence and distal metastasis was found 14 months after initial treatment. Local control is considered a principal prognostic factor for head and neck osteosarcoma.ConclusionsWide surgical excision should be considered a primary goal even during neoadjuvant chemotherapy, especially in cases that respond poorly to neoadjuvant chemotherapy.

miR-34 inhibits growth and promotes apoptosis of osteosarcoma in nude mice through targetly regulating TGIF2 expression

“…Osteosarcoma, one of the major malignant tumors, results in relatively higher mortality around the world, especially amongst adolescents and young adults [ 15–17 ]. Surgical resection combined with radiotherapy or chemotherapy is the traditional treatment for tumors currently [ 18 , 19 ]. However, patients are often accompanied by a high rate of recurrence [ 20 ].…”

Large-extension osteosarcoma with involvement of multiple maxillofacial structures: a rare case report

“…Regarding radiographic features, the sunburst pattern typical for long bone osteosarcomas are less evident in jaw bones osteosarcomas (Yildiz et al, 2014). A variety of benign lesions also clinically and morphologically overlap with low-grade osteosarcoma such as fibrous dysplasia, ossifying fibroma and desmoplastic fibroma (Demicco, Deshpande, Petur Nielsen, Kattapuram & Rosenberg, 2010;Kimura et al, 2017).…”

“…The treatment of head and neck osteosarcoma is complicated due to the absence of universal protocols (DeAngelis et al, 2012;Chen et al, 2017;Kimura et al, 2017). Surgical tumor resection is the most commonly applied therapy and may be associated with chemotherapy.…”

“…Osteosarcoma is a malignant bone tumor characterized by the formation of bone or osteoids by tumor cells (Nissanka, Amaratunge & Tilakaratne, 2007;Chen et al, 2017;Krishnamurthy & Palaniappan, 2018). The tumor most commonly appears in the metaphases of the long bones of children and adolescents, and is rare in the head and neck, comprising from 6% to 10% of all osteosarcomas and less than 1% of all cancers located in this region (Nissanka et al, 2007;Laskar et al, 2008;Chen et al, 2017;Kimura et al, 2017;Krishnamurthy & Palaniappan, 2018). Despite its rarity in the oral-maxillofacial region, it is the second most common malignancy in this location in children and adolescents (de Arruda et al, 2017).…”

The potential value of lncRNA-BC050642 in osteosarcoma origination and outcomes

“…Osteosarcoma, a most common primary malignancy in bone, represents a leading cause of cancer-related death among adolescents and young adults [1]. Despite its relatively low incidence, osteosarcoma shows soaring malignancy because of its high propensity of metastasis and local relapse [2]. Main treatments for osteosarcoma are surgical excision and chemotherapy.…”